CD274 and melanoma: Interestingly, in the adjuvant setting, results from the phase III, NCT02388906 (CheckMate 238) comparing the efficacy of nivolumab vs. ipilimumab in patients with resected stage III/IV melanoma at high risk of recurrence showed that nivolumab provides superior safety and survival compared to ipilimumab, regardless of tumor PD-L1 status.